Q1 2023

Filed Oct 16, 2025 · 10-Q · 930 days after period end · 0001493152-25-018328

Q1 2023 · 10-Q

Revenue—

Net Income

-$592.56K

N/M vs Q1 2022

EPS Diluted

$0.00

— vs Q1 2022

Operating Cash Flow-$92,775N/M

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	—	$13.76K	$22.02K	$17.12K
Net Income	-$592.56K	$5.01M	-$34.02M	$2.18M
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR